↓ Skip to main content

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Overview of attention for article published in Frontiers in oncology, June 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
Published in
Frontiers in oncology, June 2023
DOI 10.3389/fonc.2023.1210487
Pubmed ID
Authors

Ralph E. White, Maxwell Bannister, Abderrahman Day, Hannah E. Bergom, Victor M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. Drake

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 40%
Lecturer 1 20%
Unknown 2 40%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 20%
Biochemistry, Genetics and Molecular Biology 1 20%
Unknown 3 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2023.
All research outputs
#7,610,103
of 26,329,145 outputs
Outputs from Frontiers in oncology
#2,688
of 22,974 outputs
Outputs of similar age
#120,438
of 381,629 outputs
Outputs of similar age from Frontiers in oncology
#75
of 1,052 outputs
Altmetric has tracked 26,329,145 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 22,974 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,629 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1,052 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.